Document is current
Any future updates will be listed below
-
Authors
Lee, Jeoung Eun
Lee, Chang Woo
Han, A-Reum
Kim, Jina
Lee, Dong Ryul https://orcid.org/0000-0003-1534-4810
-
Funding
Funding for this research was provided by:
the National Research Foundation of Korea (2019R1A6A1A03032888, No.2022M3A9I2082319, and No.2022R1A2C1004718)
- License Information
-
More Information
Article History
Received: 29 October 2024
Accepted: 18 July 2025
First Online: 26 July 2025
Declarations
:
: All experiments using hESCs were performed with authorization from the Institutional Review Board for Human Research at CHA University, Seongnam, Korea (title of the approve project: Development of cell-therapy product for the diabetes using embryonic stem cell-derived Sertoli Cells; name of the institutional approval committee: CHA University Institutional Review Board; Approval number and date: 1044308-201712-LR-050-03 (Jun. 5, 2019), 1044308-201712-LR-050-04 (Jun. 8, 2020), 1044308-201712-LR-050-06 (Jul. 14, 2021), 1044308-201712-LR-050-07,08 (Jun. 2, 2022), and 1044308-201712-LR-050-09 (Jun. 9, 2023)).The experiments using donated human periperal blood were approved by the CHA University Institutional Review Board (title of the approve project: Study for the immune reaction of human cells in vitro and in vivo (humanized mice) with various HLA type matched blood cells derived from donated human peripheral blood and bone marrow derived blood; name of the institutional approval committee: CHA University Institutional Review Board; Approval number and date: 1044308-201803-BR-014-02 (Apr. 23,2018) and 1044308-201803-BR-014-03 (May 8, 2019)).The experimental protocols were approved by the Institutional Animal Care and Use Committee of CHA University (title of the approval project: Development of type 1 diabetes treatment using stem cell-derived insulin-secreting cells; name of the institutional approval committee: CHA University IACUC; Approval number and date: IACUC210110 (Aug. 2, 2021), IACUC220139 (Aug. 3, 2022), and IACUC230120 (Jul. 13, 2023)).The human Sertoli cells (hSCs; #4520, ScienCell, Carlsbad, CA) used for the experimental control were obtained from donors and written informed consent were obtained from the donors (). Also, human bone marrow-derived mesenchymal stem cells (hBM-MSCs; PT-2501, Lonza, Walkersville, MD) used for the experimental control were obtained from donors and written informed consent were obtained from the donors ().
: Not applicable.
: The authors declare that they have no conflict of interest.
